Macquarie Group’s BioXcel Therapeutics BTAI Stock Holding History

Macquarie Group’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-66	Closed	-$1.35K	–	1691
2024 Q2	$1.35K	Buy	+66	New	+$2.21K	﹤0.01%	1826
2022 Q4	–	Sell	-136	Closed	-$28K	–	1803
2022 Q3	$28K	Sell	136 -11	-7%	-$2.55K	﹤0.01%	2100
2022 Q2	$31K	Hold	147	–	–	﹤0.01%	2179
2022 Q1	$49	Hold	147	–	–	﹤0.01%	2146
2021 Q4	$48K	Sell	147 -53	-27%	-$22.7K	﹤0.01%	2174
2021 Q3	$97K	Buy	200 +115	+135%	+$50.6K	﹤0.01%	1993
2021 Q2	$39K	Hold	85	–	–	﹤0.01%	2205
2021 Q1	$58K	Buy	85 +46	+118%	+$37K	﹤0.01%	2032
2020 Q4	$29K	Hold	39	–	–	﹤0.01%	2148
2020 Q3	$27K	Hold	39	–	–	﹤0.01%	2091
2020 Q2	$33K	Buy	+39	New	+$25.4K	﹤0.01%	2026

Other funds holding BTAI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Macquarie Group's BTAI Position: Q3 2024 in Review

Macquarie Group sold out of BioXcel Therapeutics (BTAI) in Q3 2024, closing a stake of 66 shares — an estimated $1.35K sold.

Macquarie Group first reported a position in BTAI in Q2 2020 and held it in 11 quarters. The position peaked at $97K in Q3 2021. 49 funds tracked by Wall St. Rank hold BTAI as of Q3 2024.

Macquarie Group reported no remaining BioXcel Therapeutics position as of Q3 2024 after selling out during the quarter.
Macquarie Group sold 66 BioXcel Therapeutics shares in Q3 2024, an estimated $1.35K.
Macquarie Group first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 11 quarters.
Macquarie Group's BioXcel Therapeutics position peaked at $97K in Q3 2021.
49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.